Silo Pharma, Inc. (NASDAQ:SILO)


Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study

Dosing study of SPC-14 demonstrates efficacy for increasing memory function


Englewood Cliffs, NJ – October 20, 2022 – Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer’s disease (AD), as demonstrated in a mouse model. The research was conducted as part of a sponsored research agreement with Columbia University in New York.


SPC-14, a novel drug that combines an FDA-approved therapeutic with ketamine, is in development for the treatment of dementia related to Alzheimer’s disease. Initial data from its SPC-14 research studies shows that chronic dosing of SPC-14 resulted in increased memory in AD mice and had no negative weight effects on the subjects.


“The result from these studies is a first step in the development of SPC-14 as a potential therapeutic for the treatment of Alzheimer’s,” said Eric Weisblum Chief Executive Officer of Silo Pharma. “SPC-14 is a therapeutic that utilizes ketamine as one part of the formulation. With safety data already available from the approved therapeutic in the compound, we believe SPC-14 should be eligible for development under the FDA’s 505(b)(2) regulatory pathway. This will allow Silo Pharma to reach efficacy clinical trials faster and save costs in potentially bringing to market a potential novel new treatment for Alzheimer’s patients.


“On-going research studies are currently being conducted by Silo and we look forward to sharing these results as additional data becomes available,” Weisblum added.


Silo Pharma’s Commercial Evaluation License Agreement (CELA) with Columbia University grants an option to license two distinct assets currently under development: SPC-14 targeting Alzheimer’s disease and SPC-15 targeting stress-induced affective disorders.


About Silo Pharma 


Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as  Alzheimer’s, PTSD, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit .


Forward-Looking Statements 


This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.




Source:  Silo Pharma, Inc.

Sign Up for FREE
Stock Alerts from

to be the first to know when this emerging company issues Breaking News!

About Silo Pharma, Inc.

Committed to developing innovative solutions

Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. We are committed to developing innovative solutions to address a variety of underserved conditions.


We are committed to developing innovative solutions to address a variety of underserved conditions including Alzheimer’s; Parkinson’s; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.


While partnering with some of the leading Academic Institutions Silo has licensed therapeutics that will allow the company to pursue the more streamlined 505(b)(2) route for trials.


Silo anticipates this strategy will lower cost and allow for a faster approval process to help patients with few if any proven addressable therapeutics.


Alzheimer’s Disease

  • 6.5 million Americans suffer from Alzheimer’s and related diseases
  • ~1 in 9 Americans 65+ have Alzheimer’s
  • U.S. market for relevant drugs expected to reach $5 billion by 2027


  • Licensed from Columbia University
  • SPC-14 is a novel drug combining two approved therapeutics
  • SPC-14 targets NDMARS and 5HT4Rs to treat cognitive and
  • neuropsychiatric symptoms in Alzheimers


Growing pipeline of opportunities

  • Psychedelic drugs have shown encouraging promise
  • Licensing and funding research with transformative potential


Targeting a breadth of therapies & potentially transformative assets

  • Developing therapeutics for patients suffering from indications such as Alzheimer’s; Parkinson’s; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.
  • Silo has partnered with leading academic institutions


Gaining regulatory support

  • Silo has a faster FDA pathway utilizing 505(b)(2) pathway with various therapeutics in its pipeline


Valuable intellectual property

  • Silo has been granted patent protection and has filed numerous IP patent applications

Development timelines and current drugs in the pipeline

  • Silo Pharma believes in following the science to identify the best application for a therapeutic by targeting indications with the biggest need, and selecting the best route of delivery for patents.
  • Our current assets have shown promise in a range of illnesses and diseases, including Alzheimer’s; Parkinson’s; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.

FN Media Group LLC (FNMG) owns and operates (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty five hundred dollars for Silo Pharma, In ccurrent news coverage by the Compamy.  FNMG HOLDS NO SHARES OF Silo Pharma, Inc


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.